Haixiang Pharmaceutical (002099.SZ) invests in the company's innovative drug NWRD06 injection to complete the first phase II clinical trial

Zhitong Finance App News, Haixiang Pharmaceutical (002099.SZ) issued an announcement. The company recently received a “Notice Letter” from Beijing Guoxin Zhongshui Investment Management Co., Ltd., the manager of its industrial funds. The company learned that Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) (hereinafter referred to as “Guoxin Haixiang”) participated in the Phase II clinical trial of NWRD06, the world's first novel nucleic acid drug to prevent recurrence after liver cancer surgery, independently developed by Novell Biotech (Wuxi) Co., Ltd. (hereinafter referred to as “Novell Biotech”), which has officially launched the first clinical trial at the Cancer Hospital of the Chinese Academy of Medical Sciences.

NWRD06 injection is currently the world's first therapeutic nucleic acid drug targeting GPC3, a specific target for liver cancer, and has entered phase II clinical stage. Its mechanism for removing tumor cells by activating specific T-cell immunity is innovative. Based on this mechanism, its indications can theoretically be extended to the early treatment stage of cancer, that is, after being approved for recurrence after liver cancer surgery, there may be a possibility of challenging the indications for liver cirrhosis, and there is biological rationality for expansion; similarly, for more severe advanced liver cancer treatment, NWRD06 injection, as an immunotherapy, may be combined with existing interventional treatments and immune checkpoint inhibitors (such as PD-1 inhibitors) in the future to explore the potential for treating liver cancer.

Phase I registered clinical studies of NWRD06 injection have been completed at the Cancer Hospital of the Chinese Academy of Medical Sciences. Based on the GPC3 target treatment strategy, its core value is to accurately identify tumor cells and tiny lesions that cannot be treated with surgery, and can exert an anti-tumor effect without damaging normal tissue. With the successful launch of the phase II clinical trial and the enrollment of the first subjects, the NWRD06 injection has taken a solid step towards clinical application. In the future, it is expected to provide safe and non-invasive options to prevent recurrence for patients with liver cancer after surgery, improve the survival period of patients, and convey new health hopes.